These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Bladder Cancer, including changes in the fifth edition of the WHO Classification of Tumours: Urinary and Male Genital Tumours and how the NCCN Guidelines aligned with these updates; new and emerging treatment options for bacillus Calmette-Guérin (BCG)–unresponsive NMIBC; and updates to systemic therapy recommendations for advanced or metastatic disease.

Recent studies delineating molecular alterations in pancreatic cancer and germline alterations in individuals with pancreatic cancer highlight the need to understand the changing landscape of clinical tools available for diagnosing and treating this cancer effectively.

For many years, platinum plus etoposide regimens had been recommended for patients with extensive stage small cell lung cancer (SCLC); however, the preferred regimens for extensive stage SCLC now include immune checkpoint inhibitors, either atezolizumab or durvalumab, plus platinum plus etoposide.

Education on this topic is necessary and timely, particularly as the use of advanced practice providers (APPs) is rapidly expanding. There are a variety of models that practices can use to assign work and allocate resources; however, underutilization can result in employee satisfaction issues, high burnout, and wasted resources. This activity provides guidance and best practices on utilization of APPs.